<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38399972</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>27</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">196</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16020196</ELocationID><Abstract><AbstractText Label="UNLABELLED">A recent estimate indicates that up to 23.7 million Americans suffer from long COVID, and approximately one million workers may be out of the workforce each day due to associated symptoms, leading to a USD 50 billion annual loss of salary. Post-COVID (Long COVID) neurologic symptoms are due to the initial robust replication of SARS-CoV-2 in the nasal neuroepithelial cells, leading to inflammation of the olfactory epithelium (OE) and the central nervous system (CNS), and the OE becoming a persistent infection site. Previously, our group showed that Epigallocatechin-3-gallate-palmitate (EC16) nanoformulations possess strong antiviral activity against human coronavirus, suggesting this green tea-derived compound in nanoparticle formulations could be developed as an intranasally delivered new drug to eliminate the persistent SARS-CoV-2 infection, leading to restored olfactory function and reduced inflammation in the CNS. The objective of the current study was to determine the compatibility of the nanoformulations with human nasal primary epithelial cells (HNpECs).</AbstractText><AbstractText Label="METHODS">Nanoparticle size was measured using the ZetaView Nanoparticle Tracking Analysis (NTA) system; contact antiviral activity was determined by TCID50 assay for cytopathic effect on MRC-5 cells; post-infection inhibition activity was determined in HNpECs; and cytotoxicity for these cells was determined using an MTT assay. The rapid inactivation of OC43 (a &#x3b2;-coronavirus) and 229E (&#x3b1;-coronavirus) viruses was further characterized by transmission electron microscopy.</AbstractText><AbstractText Label="RESULTS">A saline-based nanoformulation containing 0.1% <i>w/v</i> EC16 was able to inactivate 99.9999% &#x3b2;-coronavirus OC43 on direct contact within 1 min. After a 10-min incubation of infected HNpECs with a formulation containing drug-grade EC16 (EGCG-4' mono-palmitate or EC16m), OC43 viral replication was inhibited by 99%. In addition, all nanoformulations tested for their effect on cell viability were comparable to normal saline, a regularly used nasal irrigation solution. A 1-min incubation of an EC16 nanoformulation with either OC43 or 229E showed an altered viral structure.</AbstractText><AbstractText Label="CONCLUSION">Nanoformulations containing EC16 showed properties compatible with nasal application to rapidly inactivate SARS-CoV-2 residing in the olfactory mucosa and to reduce inflammation in the CNS, pending additional formulation and safety studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Nicolette</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Oral Biology &amp; Diagnostic Sciences, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4878-2756</Identifier><AffiliationInfo><Affiliation>Camellix Research Laboratory, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Oral Biology &amp; Diagnostic Sciences, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yutao</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2870-4504</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biology and Anatomy, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hongfang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cellular Biology and Anatomy, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jingwen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3146-3812</Identifier><AffiliationInfo><Affiliation>Department of Cellular Biology and Anatomy, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Sahaj</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oral Biology &amp; Diagnostic Sciences, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Changxing Sanju Biotech Co., Ltd., Hangzhou 310013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiaocui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Changxing Sanju Biotech Co., Ltd., Hangzhou 310013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oral Biology &amp; Diagnostic Sciences, Augusta University, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Camellix Research Laboratory, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R41DC020678-01</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>BQM438CTEL</RegistryNumber><NameOfSubstance UI="C045651">epigallocatechin gallate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077330">Saline Solution</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>8R1V1STN48</RegistryNumber><NameOfSubstance UI="D002392">Catechin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077330" MajorTopicYN="N">Saline Solution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002392" MajorTopicYN="N">Catechin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EC16</Keyword><Keyword MajorTopicYN="N">EGCG-palmitate</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">nanoformulations</Keyword></KeywordList><CoiStatement>B.Y. and X.J. are associated with the EC16 manufacturer. The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>24</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>24</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38399972</ArticleId><ArticleId IdType="pmc">PMC10891529</ArticleId><ArticleId IdType="doi">10.3390/v16020196</ArticleId><ArticleId IdType="pii">v16020196</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khan A.M., Kallogjeri D., Piccirillo J.F. Growing public health concern of COVID-19 chronic olfactory dysfunction. JAMA Otolaryngol. Head. Neck Surg. 2022;148:81&#x2013;82. doi: 10.1001/jamaoto.2021.3379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2021.3379</ArticleId><ArticleId IdType="pmc">PMC8603223</ArticleId><ArticleId IdType="pubmed">34792577</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B., Xie Y., Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat. Med. 2023;29:2347&#x2013;2357. doi: 10.1038/s41591-023-02521-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02521-2</ArticleId><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie C.E., Lowe D.J., McAuley A., Mills N.L., Winter A.J., Black C., Scott J.T., O&#x2019;Donnell C.A., Blane D.N., Browne S., et al. True prevalence of long-COVID in a nationwide, population cohort study. Nat. Commun. 2023;14:7892. doi: 10.1038/s41467-023-43661-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43661-w</ArticleId><ArticleId IdType="pmc">PMC10689486</ArticleId><ArticleId IdType="pubmed">38036541</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafloo R., Majidi J., Asghari A., Aleemardani M., Kamrava S.K., Simorgh S., Seifalian A., Bagher Z., Seifalian A.M. Mechanism of Anosmia Caused by Symptoms of COVID-19 and Emerging Treatments. ACS Chem. Neurosci. 2021;12:3795&#x2013;3805. doi: 10.1021/acschemneuro.1c00477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00477</ArticleId><ArticleId IdType="pubmed">34609841</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinda B., Dinda S., Dinda M. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases. Phytomed Plus. 2023;3:100402. doi: 10.1016/j.phyplu.2022.100402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phyplu.2022.100402</ArticleId><ArticleId IdType="pmc">PMC9800022</ArticleId><ArticleId IdType="pubmed">36597465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu S. Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections. Inflamm. Allergy Drug Targets. 2015;14:13&#x2013;18. doi: 10.2174/1871528114666151022150122.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871528114666151022150122</ArticleId><ArticleId IdType="pubmed">26490660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst B.L., Dickinson D., Hsu S. Epigallocatechin-3-Gallate (EGCG) Inhibits SARS-CoV-2 Infection in Primate Epithelial Cells: A Short Communication. Microbiol. Infect. Dis. 2021;5:10. doi: 10.33425/2639-9458.1116.</Citation><ArticleIdList><ArticleId IdType="doi">10.33425/2639-9458.1116</ArticleId><ArticleId IdType="pmc">PMC8919953</ArticleId><ArticleId IdType="pubmed">35291211</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre R., de Sola S., Farr&#xe9; M., Xicota L., Cuenca-Royo A., Rodriguez J., Le&#xf3;n A., Langohr K., Gomis-Gonz&#xe1;lez M., Hernandez G., et al. A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome. Clin. Nutr. 2020;39:378&#x2013;387. doi: 10.1016/j.clnu.2019.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2019.02.028</ArticleId><ArticleId IdType="pubmed">30962103</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y., Chen P., Ling T., Wang Y., Dong R., Zhang C., Zhang L., Han M., Wang D., Wan X., et al. Certain (-)-epigallocatechin-3-gallate (EGCG) auto-oxidation products (EAOPs) retain the cytotoxic activities of EGCG. Food Chem. 2016;204:218&#x2013;226. doi: 10.1016/j.foodchem.2016.02.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2016.02.134</ArticleId><ArticleId IdType="pubmed">26988496</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J., Dickinson D., Sampath L., Hsu S. Effects of Epigallocatechin-3-Gallate-Palmitate (EC16) on In Vitro Norovirus Infection. Microbiol. Infect. Dis. 2021;5:1&#x2013;7. doi: 10.33425/2639-9458.1139.</Citation><ArticleIdList><ArticleId IdType="doi">10.33425/2639-9458.1139</ArticleId><ArticleId IdType="pmc">PMC8959116</ArticleId><ArticleId IdType="pubmed">35350749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z.-Y., Li X.-M., Liang J.-P., Xiang L.-P., Wang K.-R., Shi Y.-L., Yang R., Shi M., Ye J.-H., Lu J.-L., et al. Bioavailability of Tea Catechins and Its Improvement. Molecules. 2018;23:2346. doi: 10.3390/molecules23092346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23092346</ArticleId><ArticleId IdType="pmc">PMC6225109</ArticleId><ArticleId IdType="pubmed">30217074</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.S., Chen L., Lee M.J., Balentine D., Kuo M.C., Schantz S.P. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol. Biomark. Prev. 1998;7:351&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">9568793</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Z., Xu Y., Yin J.F., Jin J., Jiang Y., Du Q. Improving the Effectiveness of (-)-Epigallocatechin Gallate (EGCG) against Rabbit Atherosclerosis by EGCG-Loaded Nanoparticles Prepared from Chitosan and Polyaspartic Acid. J. Agric. Food Chem. 2014;62:12603&#x2013;12609. doi: 10.1021/jf504603n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf504603n</ArticleId><ArticleId IdType="pubmed">25483592</ArticleId></ArticleIdList></Reference><Reference><Citation>Farabegoli F., Granja A., Magalh&#xe3;es J., Purgato S., Voltattorni M., Pinheiro M. Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines. ACS Omega. 2022;7:41872&#x2013;41881. doi: 10.1021/acsomega.2c01829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.2c01829</ArticleId><ArticleId IdType="pmc">PMC9685782</ArticleId><ArticleId IdType="pubmed">36440117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng L., Yan J., Luo L., Ma M., Zhu H. Preparation and characterization of (-)-Epigallocatechin-3-gallate (EGCG)-loaded nanoparticles and their inhibitory effects on Human breast cancer MCF-7 cells. Sci. Rep. 2017;7:45521. doi: 10.1038/srep45521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep45521</ArticleId><ArticleId IdType="pmc">PMC5368574</ArticleId><ArticleId IdType="pubmed">28349962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Liu Z., Liang X., Wang S., Ding J., Li Z., Wang L., Jiang Y. Preparation and characterization of epigallocatechin-3-gallate loaded melanin nanocomposite (EGCG @MNPs) for improved thermal stability, antioxidant and antibacterial activity. LWT Food Sci. Technol. 2022;154:112599. doi: 10.1016/j.lwt.2021.112599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lwt.2021.112599</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N.A., Bhardwaj V., Ravi C., Ramesh N., Mandal A.K.A., Khan Z.A. EGCG Nanoparticles Attenuate Aluminum Chloride Induced Neurobehavioral Deficits, Beta Amyloid and Tau Pathology in a Rat Model of Alzheimer&#x2019;s Disease. Ftontiers Aging Neurosci. 2018;10:244. doi: 10.3389/fnagi.2018.00244.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00244</ArticleId><ArticleId IdType="pmc">PMC6099078</ArticleId><ArticleId IdType="pubmed">30150930</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano A., Ettcheto M., Espina M., Auladell C., Calpena A.C., Folch J., Barenys M., S&#xe1;nchez-L&#xf3;pez E., Camins A., Garc&#xed;a M.L. Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. Nanomed. Nanotechnol. Biol. Med. 2018;14:1073&#x2013;1085. doi: 10.1016/j.nano.2018.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2018.01.019</ArticleId><ArticleId IdType="pubmed">29454994</ArticleId></ArticleIdList></Reference><Reference><Citation>Giunchedi P., Gavini E., Bonferoni M.C. Nose-to-Brain Delivery. Pharmaceutics. 2020;12:138. doi: 10.3390/pharmaceutics12020138.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12020138</ArticleId><ArticleId IdType="pmc">PMC7076467</ArticleId><ArticleId IdType="pubmed">32041344</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A.R., Yang X., Fu M., Zhai G. Recent progress of drug nanoformulations targeting to brain. J. Control. Release. 2018;291:37&#x2013;64. doi: 10.1016/j.jconrel.2018.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2018.10.004</ArticleId><ArticleId IdType="pubmed">30308256</ArticleId></ArticleIdList></Reference><Reference><Citation>Maaz A., Blagbrough I.S., De Bank P.A. In Vitro Evaluation of Nasal Aerosol Depositions: An Insight for Direct Nose to Brain Drug Delivery. Pharmaceutics. 2021;13:1079. doi: 10.3390/pharmaceutics13071079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13071079</ArticleId><ArticleId IdType="pmc">PMC8309016</ArticleId><ArticleId IdType="pubmed">34371770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonferoni M.C., Rassu G., Gavini E., Sorrenti M., Catenacci L., Giunchedi P. Nose-to-Brain Delivery of Antioxidants as a Potential Tool for the Therapy of Neurological Diseases. Pharmaceutics. 2020;12:1246. doi: 10.3390/pharmaceutics12121246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12121246</ArticleId><ArticleId IdType="pmc">PMC7766211</ArticleId><ArticleId IdType="pubmed">33371285</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank N., Dickinson D., Garcia W., Xiao L., Xayaraj A., Lee L.H., Chu T., Kumar M., Stone S., Liu Y., et al. Evaluation of Aqueous Nanoformulations of Epigallocatechin-3-Gallate-Palmitate (EC16) against Human Coronavirus as a Potential Intervention Drug. Biomed. J. Sci. Tech. Res. 2023;50:2023</Citation></Reference><Reference><Citation>Helwa I., Cai J., Drewry M.D., Zimmerman A., Dinkins M.B., Khaled M.L., Seremwe M., Dismuke W.M., Bieberich E., Stamer W.D., et al. A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents. PLoS ONE. 2017;12:e0170628. doi: 10.1371/journal.pone.0170628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0170628</ArticleId><ArticleId IdType="pmc">PMC5256994</ArticleId><ArticleId IdType="pubmed">28114422</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungnak W., Huang N., B&#xe9;cavin C., Berg M., Queen R., Litvinukova M., Talavera-L&#xf3;pez C., Maatz H., Reichart D., Sampaziotis F., et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020;26:681&#x2013;687. doi: 10.1038/s41591-020-0868-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0868-6</ArticleId><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs C.E., Wen G.Y., Xu W., Jia J.H., Rohan L., Corbo C., Di Maggio V., Jenkins E.C., Jr., Hillier S. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob. Agents Chemother. 2008;52:962&#x2013;970. doi: 10.1128/AAC.00825-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00825-07</ArticleId><ArticleId IdType="pmc">PMC2258520</ArticleId><ArticleId IdType="pubmed">18195068</ArticleId></ArticleIdList></Reference><Reference><Citation>Clementino A.R., Pellegrini G., Banella S., Colombo G., Cantu L., Sonvico F., Del Favero E. Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs. Mol. Pharm. 2021;18:3132&#x2013;3146. doi: 10.1021/acs.molpharmaceut.1c00366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.1c00366</ArticleId><ArticleId IdType="pmc">PMC8335725</ArticleId><ArticleId IdType="pubmed">34259534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.I., Lee C. Human Coronavirus OC43 as a Low-Risk Model to Study COVID-19. Viruses. 2023;15:578. doi: 10.3390/v15020578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020578</ArticleId><ArticleId IdType="pmc">PMC9965565</ArticleId><ArticleId IdType="pubmed">36851792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>